BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs....

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, Merope, Scotto, Daniele, Josephs, Debra H., Mele, Silvia, Crescioli, Silvia, Bax, Heather J., Pellizzari, Giulia, Wynne, Matthew D., Nakamura, Mano, Hoffmann, Ricarda M., Ilieva, Kristina M., Cheung, Anthony, Spicer, James F., Papa, Sophie, Lacy, Katie E., Karagiannis, Sophia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652848/
https://www.ncbi.nlm.nih.gov/pubmed/29100459
http://dx.doi.org/10.18632/oncotarget.19836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652848/
https://www.ncbi.nlm.nih.gov/pubmed/29100459
http://dx.doi.org/10.18632/oncotarget.19836

Ejemplares similares